High-dose intravenous fluoroquinolones in the treatment of severe infections

Journal of Chemotherapy

Volumn 11, Issue 6, 1999, Pages 478-485

  Modai, J ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Ciprofloxacin; Fluoroquinolones; Levofloxacin; Nosocomial infections; Ofloxacin; Pefloxacin; Trovafloxaci n

Indexed keywords

ALATROFLOXACIN; CIPROFLOXACIN; GYRASE INHIBITOR; LEVOFLOXACIN; OFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ALLERGIC REACTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; HOSPITAL INFECTION; HUMAN; NAUSEA; PSEUDOMONAS AERUGINOSA; RASH; SEIZURE; STAPHYLOCOCCUS;

EID: 0033378852     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1999.11.6.478     Document Type: Conference Paper

References (15)

1. rd edn. Boston: Little-Brown, 1992.
2. 2 Phillips I, King A, Shannon K. In vitro properties of the quinolones. In: The Quinolones, Andriole VT, ed. Academic Press, 1998: 81-116.
3. 3 Cunha BA, Hussain Quadri SM, Ueni Y, Walters EA, Domenico P. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates. J Antimicrob Chemother 1997; 39 (suppl B): 29-34.
4. 4 Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin and ciprofloxacin. J Antimicrob Chemother 1997; 40: 639-651.
5. 5 Giamarellou H, Mandragos K, Bechrakis P, Pigas K, Bilalis D, Sfikakis P. Pefloxacin versus imipenem in the therapy of nosocomial lung infections of intensive care unit patients. J Antimicrob Chemother 1990; 26, Suppl B: 117-127.
6. 6 Segev S, Rosen N, Joseph G, Elran HA, Rubinstein E. Pefloxacin efficacy in gram-negative bacillary meningitis. J Antimicrob Chemother 1990; 26, Suppl B: 187-192.
7. 7 Graninger W, Presterl E, Walzl B, Lackner R, Haslinger B, Hackl W. Intravenous ofloxacin in severe infections. J Antimicrob Chemother 1990; 26, Suppl D: 123-135.
8. 8 Gentry LO, Rodriguez-Gomez G, Kohler RB, Khan FA, Rytel MW. Parenteral followed by oral ofloxacin for nosocomial pneumonia and community-acquired pneumonia requiring hospitalization. Am Rev Respir Dis 1992; 145: 31-35.
9. 9 Neu HC, Davidson S, Briones F. Intravenous/oral ciprofloxacin therapy of infections caused by multiresistant bacteria. Am J Med 1989; 87(5A): 209S-212S.
10. 10 Kljucar S, Heimesaat M, von Pritzbuer E, Timm J, Bauernfeind A. A comparison of intravenous ciprofloxacin dosage regimens in severe nosocomial infections. In Clinical Pharmacology of IV Ciprofloxacin, Infect Med 1992; Suppl.
11. 11 Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother 1994; 38(3): 547-557.
12. 12 Krumpe PE, Cohn S, Garrcltes J, Ramirez J, Coulter H, Haverstock D, Echols and the Ciprofloxacin Study Group. Intravenous and oral mono-or combination-therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy. J Antimicrob Chemother 1999; 43, Suppl. A: 117-128.
13. 13 File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41(9): 1965-1972.
14. 14 Norrby RS, Petermann W, Willcox PA, Vetter N, Salewski E. Levofloxacin versus ceftriaxone in the treatment of pneumonia in hospitalised patients. European Congress of Chemotherapy, Hamburg, 1998, poster #130.
15. 15 Donahue PE, Smith DL, Yellin AE, Mintz SJ, Bur F, Luke DR and the Trovafloxacin Surgical Group. Trovafloxacin in the treatment of intraabdominal infections: results of a double-blind, multicenter comparison with imipenem/cilastatin. Am J Surg 1998; 176 (suppl 6A): 53S-61S.